Sakurako Suma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sakurako Suma has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Mamiko Sakata-Yanagimoto
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
6 shared publications - Kenichi Makishima
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
5 shared publications - Shigeru Chiba
Institute of Medicine, University of Tsukuba
5 shared publications - Yoshiaki Abe
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
5 shared publications - Manabu Fujisawa
Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
4 shared publications - Tatsuhiro Sakamoto
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
4 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas
- 5 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessA multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas
- 29 September 2026
- Published by Wiley in Pathology International
- Vol. 76  (9) , e70186
Pathological Diagnosis of Nodal T Follicular Helper Cell Lymphoma, Angioimmunoblastic Type
We herein review the pathological diagnosis of nodal T follicular helper (TFH) cell lymphoma, angioimmunoblastic type (nTFHLâAI), a mature Tâcell neoplasm with a TFH phenotype that was previously designated as angioimmunoblastic Tâcell lymphoma (AITL). The history of AITL from its discovery to the WHO 5th classification, which includes Japanese pathologists' and hematologists' contributions, is discussed. We then focus on what true neoplastic T cells of nTFHLâAl are in histopathology. Since the number of neoplastic cells is small in some cases of nTFHLâAI, the findings of recent singleâcell analyses to immunohistochemistry of TFH markers are considered. We also discuss EpsteinâBarr virus large Bâcells in AITL, particularly diffuse large Bâcell lymphoma and classic Hodgkin lymphoma (CHL), and propose how to make a differential diagnosis between nTFHLâAl and CHL.
- 29 September 2026
- Published by Wiley in Pathology International
- Vol. 76  (9) , e70186
Pathological Diagnosis of Nodal T Follicular Helper Cell Lymphoma, Angioimmunoblastic Type
We herein review the pathological diagnosis of nodal T follicular helper (TFH) cell lymphoma, angioimmunoblastic type (nTFHLâAI), a mature Tâcell neoplasm with a TFH phenotype that was previously designated as angioimmunoblastic Tâcell lymphoma (AITL). The history of AITL from its discovery to the WHO 5th classification, which includes Japanese pathologists' and hematologists' contributions, is discussed. We then focus on what true neoplastic T cells of nTFHLâAl are in histopathology. Since the number of neoplastic cells is small in some cases of nTFHLâAI, the findings of recent singleâcell analyses to immunohistochemistry of TFH markers are considered. We also discuss EpsteinâBarr virus large Bâcells in AITL, particularly diffuse large Bâcell lymphoma and classic Hodgkin lymphoma (CHL), and propose how to make a differential diagnosis between nTFHLâAl and CHL.
- Open Access
- 27 November 2023
- Published by Springer Nature in Leukemia
- Vol. 38  (2) , 340-350
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution
T follicular helper (TFH) cell lymphomas (TFHLs) are characterized by TFH-like properties and accompanied by substantial immune-cell infiltration into tumor tissues. Nevertheless, the comprehensive understanding of tumor-cell heterogeneity and immune profiles of TFHL remains elusive. To address this, we conducted single-cell transcriptomic analysis on 9 lymph node (LN) and 16 peripheral blood (PB) samples from TFHL patients. Tumor cells were divided into 5 distinct subclusters, with significant heterogeneity observed in the expression levels of TFH markers. Copy number variation (CNV) and trajectory analyses indicated that the accumulation of CNVs, together with gene mutations, may drive the clonal evolution of tumor cells towards TFH-like and cell proliferation phenotypes. Additionally, we identified a novel tumor-cell-specific marker, PLS3. Notably, we found a significant increase in exhausted CD8+ T cells with oligoclonal expansion in TFHL LNs and PB, along with distinctive immune evasion characteristics exhibited by infiltrating regulatory T, myeloid, B, and natural killer cells. Finally, in-silico and spatial cell-cell interaction analyses revealed complex networking between tumor and immune cells, driving the formation of an immunosuppressive microenvironment. These findings highlight the remarkable tumor-cell heterogeneity and immunoevasion in TFHL beyond previous expectations, suggesting potential roles in treatment resistance.
- 27 November 2023
- Published by Springer Nature in Leukemia
- Vol. 38  (2) , 340-350
Open AccessTumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution
T follicular helper (TFH) cell lymphomas (TFHLs) are characterized by TFH-like properties and accompanied by substantial immune-cell infiltration into tumor tissues. Nevertheless, the comprehensive understanding of tumor-cell heterogeneity and immune profiles of TFHL remains elusive. To address this, we conducted single-cell transcriptomic analysis on 9 lymph node (LN) and 16 peripheral blood (PB) samples from TFHL patients. Tumor cells were divided into 5 distinct subclusters, with significant heterogeneity observed in the expression levels of TFH markers. Copy number variation (CNV) and trajectory analyses indicated that the accumulation of CNVs, together with gene mutations, may drive the clonal evolution of tumor cells towards TFH-like and cell proliferation phenotypes. Additionally, we identified a novel tumor-cell-specific marker, PLS3. Notably, we found a significant increase in exhausted CD8+ T cells with oligoclonal expansion in TFHL LNs and PB, along with distinctive immune evasion characteristics exhibited by infiltrating regulatory T, myeloid, B, and natural killer cells. Finally, in-silico and spatial cell-cell interaction analyses revealed complex networking between tumor and immune cells, driving the formation of an immunosuppressive microenvironment. These findings highlight the remarkable tumor-cell heterogeneity and immunoevasion in TFHL beyond previous expectations, suggesting potential roles in treatment resistance.
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 430
Distinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization
Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 430
Open AccessDistinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization
Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 5608
Investigation of Clonal Hematopoiesis in New Japanese Cohort
Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 5608
Open AccessInvestigation of Clonal Hematopoiesis in New Japanese Cohort
Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7  (S3) , e1725993
S237: THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7  (S3) , e1725993
Open AccessS237: THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA
- Open Access
- 3 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140  (18) , 1937-1950
Clonal germinal center B cells function as a niche for T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40âCd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40âCD40LG axis.
- 3 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140  (18) , 1937-1950
Open AccessClonal germinal center B cells function as a niche for T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40âCd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40âCD40LG axis.
- 24 December 2020
- Published by American Society of Hematology in Blood
- Vol. 136  (26) , 3018-3032
VAV1 mutations contribute to development of T-cell neoplasms in mice
Activating mutations in the Vav guanine nucleotide exchange factor 1 (VAV1) gene are reported in various subtypes of mature T-cell neoplasms (TCNs). However, oncogenic activities associated with VAV1 mutations in TCNs remain unclear. To define them, we established transgenic mice expressing VAV1 mutants cloned from human TCNs. Although we observed no tumors in these mice for up to a year, tumors did develop in comparably aged mice on a p53-null background (p53â/âVAV1-Tg), and p53â/âVAV1-Tg mice died with shorter latencies than did p53-null (p53â/â) mice. Notably, various TCNs with tendency of maturation developed in p53â/âVAV1-Tg mice, whereas p53â/â mice exhibited only immature TCNs. Mature TCNs in p53â/âVAV1-Tg mice mimicked a subtype of human peripheral T-cell lymphoma (PTCL-GATA3) and exhibited features of type 2 T helper (Th2) cells. Phenotypes seen following transplantation of either p53â/âVAV1 or p53â/â tumor cells into nude mice were comparable, indicating cell-autonomous tumor-initiating capacity. Whole-transcriptome analysis showed enrichment of multiple Myc-related pathways in TCNs from p53â/âVAV1-Tg mice relative to p53â/â or wild-type T cells. Remarkably, amplification of the Myc locus was found recurrently in TCNs of p53â/âVAV1-Tg mice. Finally, treatment of nude mice transplanted with p53â/âVAV1-Tg tumor cells with JQ1, a bromodomain inhibitor that targets the Myc pathway, prolonged survival of mice. We conclude that VAV1 mutations function in malignant transformation of T cells in vivo and that VAV1-mutantâexpressing mice could provide an efficient tool for screening new therapeutic targets in TCNs harboring these mutations.
- 24 December 2020
- Published by American Society of Hematology in Blood
- Vol. 136  (26) , 3018-3032
VAV1 mutations contribute to development of T-cell neoplasms in mice
Activating mutations in the Vav guanine nucleotide exchange factor 1 (VAV1) gene are reported in various subtypes of mature T-cell neoplasms (TCNs). However, oncogenic activities associated with VAV1 mutations in TCNs remain unclear. To define them, we established transgenic mice expressing VAV1 mutants cloned from human TCNs. Although we observed no tumors in these mice for up to a year, tumors did develop in comparably aged mice on a p53-null background (p53â/âVAV1-Tg), and p53â/âVAV1-Tg mice died with shorter latencies than did p53-null (p53â/â) mice. Notably, various TCNs with tendency of maturation developed in p53â/âVAV1-Tg mice, whereas p53â/â mice exhibited only immature TCNs. Mature TCNs in p53â/âVAV1-Tg mice mimicked a subtype of human peripheral T-cell lymphoma (PTCL-GATA3) and exhibited features of type 2 T helper (Th2) cells. Phenotypes seen following transplantation of either p53â/âVAV1 or p53â/â tumor cells into nude mice were comparable, indicating cell-autonomous tumor-initiating capacity. Whole-transcriptome analysis showed enrichment of multiple Myc-related pathways in TCNs from p53â/âVAV1-Tg mice relative to p53â/â or wild-type T cells. Remarkably, amplification of the Myc locus was found recurrently in TCNs of p53â/âVAV1-Tg mice. Finally, treatment of nude mice transplanted with p53â/âVAV1-Tg tumor cells with JQ1, a bromodomain inhibitor that targets the Myc pathway, prolonged survival of mice. We conclude that VAV1 mutations function in malignant transformation of T cells in vivo and that VAV1-mutantâexpressing mice could provide an efficient tool for screening new therapeutic targets in TCNs harboring these mutations.